Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_3
1
25%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)

Trials by Status

recruiting125%
completed375%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_1

Venetoclax to Augment Epigenetic Modification and Chemotherapy

NCT05317403
completedphase_2

Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

NCT02845297
completedphase_1

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

NCT02265731
completedphase_3

Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02319135

Clinical Trials (4)

Showing 4 of 4 trials
NCT05317403Phase 1

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Recruiting
NCT02845297Phase 2

Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

Completed
NCT02265731Phase 1

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Completed
NCT02319135Phase 3

Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4